DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder
So far, genetic studies of treatment response in schizophrenia, bipolar disorder, and major depression have returned results with limited clinical utility. A gene × environment interplay has been proposed as a factor influencing not only pathophysiology but also the treatment response. The...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/19/10/3026 |
id |
doaj-1d142474063d462bb639993ca98fa2b2 |
---|---|
record_format |
Article |
spelling |
doaj-1d142474063d462bb639993ca98fa2b22020-11-25T00:50:07ZengMDPI AGInternational Journal of Molecular Sciences1422-00672018-10-011910302610.3390/ijms19103026ijms19103026DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive DisorderCharanraj Goud Alladi0Bruno Etain1Frank Bellivier2Cynthia Marie-Claire3Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry 605006, IndiaINSERM U1144 Variabilité de réponse aux psychotropes, Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, FranceINSERM U1144 Variabilité de réponse aux psychotropes, Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, FranceINSERM U1144 Variabilité de réponse aux psychotropes, Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, FranceSo far, genetic studies of treatment response in schizophrenia, bipolar disorder, and major depression have returned results with limited clinical utility. A gene × environment interplay has been proposed as a factor influencing not only pathophysiology but also the treatment response. Therefore, epigenetics has emerged as a major field of research to study the treatment of these three disorders. Among the epigenetic marks that can modify gene expression, DNA methylation is the best studied. We performed a systematic search (PubMed) following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA guidelines for preclinical and clinical studies focused on genome-wide and gene-specific DNA methylation in the context of schizophrenia, bipolar disorders, and major depressive disorder. Out of the 112 studies initially identified, we selected 31 studies among them, with an emphasis on responses to the gold standard treatments in each disorder. Modulations of DNA methylation levels at specific CpG sites have been documented for all classes of treatments (antipsychotics, mood stabilizers, and antidepressants). The heterogeneity of the models and methodologies used complicate the interpretation of results. Although few studies in each disorder have assessed the potential of DNA methylation as biomarkers of treatment response, data support this hypothesis for antipsychotics, mood stabilizers and antidepressants.http://www.mdpi.com/1422-0067/19/10/3026schizophreniabipolar disordermajor depressive disorderDNA methylationresponse variability |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Charanraj Goud Alladi Bruno Etain Frank Bellivier Cynthia Marie-Claire |
spellingShingle |
Charanraj Goud Alladi Bruno Etain Frank Bellivier Cynthia Marie-Claire DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder International Journal of Molecular Sciences schizophrenia bipolar disorder major depressive disorder DNA methylation response variability |
author_facet |
Charanraj Goud Alladi Bruno Etain Frank Bellivier Cynthia Marie-Claire |
author_sort |
Charanraj Goud Alladi |
title |
DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder |
title_short |
DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder |
title_full |
DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder |
title_fullStr |
DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder |
title_full_unstemmed |
DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder |
title_sort |
dna methylation as a biomarker of treatment response variability in serious mental illnesses: a systematic review focused on bipolar disorder, schizophrenia, and major depressive disorder |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2018-10-01 |
description |
So far, genetic studies of treatment response in schizophrenia, bipolar disorder, and major depression have returned results with limited clinical utility. A gene × environment interplay has been proposed as a factor influencing not only pathophysiology but also the treatment response. Therefore, epigenetics has emerged as a major field of research to study the treatment of these three disorders. Among the epigenetic marks that can modify gene expression, DNA methylation is the best studied. We performed a systematic search (PubMed) following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA guidelines for preclinical and clinical studies focused on genome-wide and gene-specific DNA methylation in the context of schizophrenia, bipolar disorders, and major depressive disorder. Out of the 112 studies initially identified, we selected 31 studies among them, with an emphasis on responses to the gold standard treatments in each disorder. Modulations of DNA methylation levels at specific CpG sites have been documented for all classes of treatments (antipsychotics, mood stabilizers, and antidepressants). The heterogeneity of the models and methodologies used complicate the interpretation of results. Although few studies in each disorder have assessed the potential of DNA methylation as biomarkers of treatment response, data support this hypothesis for antipsychotics, mood stabilizers and antidepressants. |
topic |
schizophrenia bipolar disorder major depressive disorder DNA methylation response variability |
url |
http://www.mdpi.com/1422-0067/19/10/3026 |
work_keys_str_mv |
AT charanrajgoudalladi dnamethylationasabiomarkeroftreatmentresponsevariabilityinseriousmentalillnessesasystematicreviewfocusedonbipolardisorderschizophreniaandmajordepressivedisorder AT brunoetain dnamethylationasabiomarkeroftreatmentresponsevariabilityinseriousmentalillnessesasystematicreviewfocusedonbipolardisorderschizophreniaandmajordepressivedisorder AT frankbellivier dnamethylationasabiomarkeroftreatmentresponsevariabilityinseriousmentalillnessesasystematicreviewfocusedonbipolardisorderschizophreniaandmajordepressivedisorder AT cynthiamarieclaire dnamethylationasabiomarkeroftreatmentresponsevariabilityinseriousmentalillnessesasystematicreviewfocusedonbipolardisorderschizophreniaandmajordepressivedisorder |
_version_ |
1725249281161428992 |